Global Non-Alcoholic Steatohepatitis Biomarkers Industry Insights: Key Trends and Growth Estimates
Uncover key drivers, emerging technologies, and competitive movements shaping the worker heat stress monitoring wearable market from 2026–2035 with trusted insights from The Business Research Company
Starting from its 2026 valuation, what market size is the Non-Alcoholic Steatohepatitis Biomarkers Market expected to reach by 2030?
The non-alcoholic steatohepatitis biomarkers market size has seen significant expansion in recent years. It is anticipated to grow from $1.68 billion in 2025 to $2.08 billion in 2026, at a compound annual growth rate (CAGR) of 23.2%. The growth experienced in the past can be attributed to the increasing prevalence of metabolic disorders, a rise in the incidence of obesity and type 2 diabetes, the expansion of liver disease research programs, the availability of advanced diagnostic assays, and a growing pharmaceutical interest in NASH therapies.
The non-alcoholic steatohepatitis biomarkers market is projected to experience substantial expansion in the coming years. Its valuation is anticipated to reach $4.6 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 22.0%. This growth trajectory during the forecast period is fueled by heightened investments in precision hepatology, a growing need for non-invasive diagnostic instruments, the broadening scope of biomarker-guided clinical trials, increasing uptake of personalized medical strategies, and an intensified focus on managing diseases in their early stages. Key developments anticipated within this timeframe involve the heightened creation of non-invasive diagnostic biomarkers, increasing application of serum-based NASH biomarkers, the expanding integration of AI in biomarker analytical processes, a wider deployment of companion diagnostics within drug development, and an amplified emphasis on identifying diseases at an early stage.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp
What Drivers Are Driving Adoption Within The Non-Alcoholic Steatohepatitis Biomarkers Market?
The increasing occurrence of liver cancer is anticipated to boost the expansion of the non-alcoholic steatohepatitis biomarkers market in the future. Liver cancer involves the formation of cancerous growths inside the liver, originating either within the liver itself (known as primary liver cancer) or spreading to it from elsewhere in the body (referred to as secondary or metastatic liver cancer). In cases of liver cancer, non-alcoholic steatohepatitis (NASH) biomarkers find application in early diagnosis, tracking disease advancement, evaluating treatment efficacy, offering prognostic data, and potentially lessening the requirement for invasive medical interventions. For example, projections from July 2025, published by the UK-based cancer journal ecancer medical science, suggest that the number of new liver cancer cases is projected to nearly double from 870,000 in 2022 to 1.52 million by 2050. This increase is primarily attributed to population growth and ageing, with the most significant surges expected in Africa. Furthermore, liver cancer fatalities are also forecast to rise from 760,000 in 2022 to 1.37 million by 2050. Consequently, the expanding incidence of liver cancer is a key factor propelling the expansion of the non-alcoholic steatohepatitis biomarkers market.
What Segments Are Included Within The Non-Alcoholic Steatohepatitis Biomarkers Market?
The non-alcoholic steatohepatitis biomarkers market covered in this report is segmented –
1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Technology: Enzyme-Linked Immunosorbent Assay (ELISA), Mass Spectrometry, Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Other Technologies
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses
Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers
Which Trends Are Influencing The Performance And Direction Of The Non-Alcoholic Steatohepatitis Biomarkers Market?
Major companies operating in the non-alcoholic steatohepatitis biomarkers market are integrating advanced biomarker-platform technologies, such as multi-analyte fibrosis-scoring assays, to enhance non-invasive disease assessment and the stratification of patient risk. These assays work by measuring multiple fibrosis-related proteins in a single blood sample and applying an algorithm to generate a numerical score, thereby enabling prognostic evaluation and supporting the identification of advanced fibrosis. For instance, in July 2023, Siemens Healthineers, a Germany-based medical-technology company, secured breakthrough device designation from the US Food and Drug Administration for its Enhanced Liver Fibrosis Test, which is a multi-analyte fibrosis-scoring assay designed to support identification of advanced fibrosis and cirrhosis in individuals with non-alcoholic fatty liver disease, distinguished by a numerical score derived from three direct fibrosis biomarkers. The test aids in the earlier clinical evaluation of liver disease severity and lessens reliance on invasive biopsy.
Who Are The Major Companies Operating In The Non-Alcoholic Steatohepatitis Biomarkers Market?
Major companies operating in the non-alcoholic steatohepatitis biomarkers market are Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine
Access The Complete Report For Deeper Market Insights:
Which Region Is Anticipated To See The Fastest Growth In The Non-Alcoholic Steatohepatitis Biomarkers Market?
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Non-Alcoholic Steatohepatitis Biomarkers Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=9002&type=smp
Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Biomarkers Market 2026, By The Business Research Company
Non Alcoholic Steatohepatitis Treatment Global Market Report 2026
Non Alcoholic Steatohepatitis Treatment Global Market Report 2026
Fatty Liver Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
